Trial Profile
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Citarinostat (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 03 Jan 2024 Planned End Date changed from 30 Jun 2023 to 31 Jan 2024.
- 03 Jan 2024 Planned primary completion date changed from 30 Jun 2023 to 31 Jan 2024.
- 16 Sep 2022 Planned number of patients changed from 41 to 16.